Working to Eradicate Gynecologic Cancers

449 - Poster Session B
Adverse event profile by folate receptor status for vintafolide+pegylated liposomal doxorubicin vs pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

Sunday, March 23, 2014: 7:20 PM
West Exhibit Hall (Tampa Convention Center)
T. J. Herzog1, E. Kutarska2, M. Bidzinski3, J. Symanowski4, B. Nguyen5, R. Rangwala6 and R. W. Naumann7
1Columbia University & Herbert Irving Comprehensive Cancer Center, New York, NY, 2Centrum Onkologii Ziemi Lubelskiej, Lublin, Poland, 3Holycross Cancer Center, Kielce, Poland, 4Levine Cancer Institute, Charlotte, NC, 5Endocyte, Inc, West Lafayette, IN, 6Merck Research Laboratories, North Wales, PA, 7Carolinas Medical Center, Charlotte, NC
 
See more of: Poster Session B
See more of: Poster Session
<< Previous Presentation | Next Presentation >>